[PDF][PDF] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
LV Sequist, JCH Yang, N Yamamoto… - Journal of clinical …, 2013 - static.vademecum.es
Journal of clinical oncology, 2013•static.vademecum.es
Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling
from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor
receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against
EGFR mutations. A phase II study of afatinib in EGFR mutation–positive lung
adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling
from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor
receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against
EGFR mutations. A phase II study of afatinib in EGFR mutation–positive lung
adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
Purpose
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation–positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
static.vademecum.es
